# Ionis Pharmaceuticals, Inc. (IONS) FY2026 Q2 Balance Sheet

- Company: Ionis Pharmaceuticals, Inc. (IONS)
- Period: As of 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-07-29, accession number 0000874015-26-000251
- Page: https://plicit.ai/financials/ions/fy2026-q2-balance-sheet
- Chart image: https://plicit.ai/charts/ions-fy2026-q2-balance-sheet-sankey.png

## Chart details

Balance sheet as of 2026-06-30. The chart shows assets, liabilities and equity at that date.

- **Assets**: 2,994,501,000 US dollars
- **Current assets**: 2,491,274,000 US dollars
- **Non-current assets**: 503,227,000 US dollars
- **Liabilities**: 2,554,764,000 US dollars
- **Current liabilities**: 315,638,000 US dollars
- **Non-current liabilities**: 2,239,126,000 US dollars
- **Equity**: 439,737,000 US dollars
- **Short-term investments**: 1,704,520,000 US dollars
- **Cash and cash equivalents**: 350,065,000 US dollars
- **Other current assets**: 327,011,000 US dollars
- **Contracts receivable**: 58,845,000 US dollars
- **Inventories**: 50,833,000 US dollars
- **Right-of-use assets**: 231,560,000 US dollars
- **Property, plant and equipment, net**: 155,131,000 US dollars
- **Deposits and other assets**: 116,536,000 US dollars
- **Accrued liabilities**: 115,778,000 US dollars
- **Current portion of deferred contract revenue**: 73,837,000 US dollars
- **Accrued compensation**: 50,293,000 US dollars
- **Accounts payable**: 47,704,000 US dollars
- **Other current liabilities**: 25,149,000 US dollars
- **Income taxes payable**: 2,877,000 US dollars
- **0 percent convertible senior notes due April 2026, net**: 0 US dollars
- **Convertible senior notes, net - 0% Notes due 2030**: 753,356,000 US dollars
- **Convertible senior notes, net - 1.75% Notes due 2028**: 569,255,000 US dollars
- **Liability related to sale of future royalties, net**: 562,574,000 US dollars
- **Long-term lease liabilities**: 262,476,000 US dollars
- **Long-term deferred contract revenue**: 63,030,000 US dollars
- **Long-term obligations**: 28,435,000 US dollars
- **Additional paid-in capital**: 3,311,837,000 US dollars
- **Common stock, $0.001 par value; 300,000,000 shares authorized, 165,636,792 and 163,304,875 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively**: 166,000 US dollars
- **Accumulated deficit**: negative 2,838,369,000 US dollars
- **Accumulated other comprehensive loss**: negative 33,897,000 US dollars
- **Gross equity (calculated)**: 3,312,003,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

### Chart connections

- Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
- Treasury shares and other negative equity contributions reduce equity.